Figure 6: Effects of SSOs on BCLAF1 alterative splicing modulation.

(a) Schematic diagram of splicing-switching oligos SSO1 and SSO2, plus control oligo INV-SSO2 that were designed against 3′-splice site at the boundary of intron4 and exon5a of BCLAF1 pre-mRNA. (b) RKO or HCT116 cells were treated with indicated SSOs. After 96 h, cells were harvested and total RNA was extracted. BCLAF1 exon5a splice variants were analysed by RT–PCR. (c) RKO cells were treated with indicated SSO for 72 h and crystal violate staining was performed to show decreased cell viability after SSO treatment. Quantification of relative cell viability was shown below. At least three experiments were repeated and results are shown as mean±s.d. (d) Clonogenic survival assays and qualification of RKO cells after treatment with indicated SSO were performed, as described in Fig. 2c,d. The experiments were repeated at least three times and results are shown as mean±s.d.